Every letter we have printed

I train four times a week, eat a hundred and sixty grams of protein and my appendicular lean mass has fallen by 1.8 kg over ten months while every lift has gone up. Your section on mass against function was the first thing I have read that made that seem normal rather than a failure.

Small correction to your table: the S-LiTE exercise prescription was two supervised group sessions and two individual sessions weekly, not two sessions in total. The distinction matters because "add some exercise" is not what was tested.

I am sixty-eight, I have lost nineteen kilograms over fourteen months, and my consultant has twice told me my lean mass is fine on the basis of a handheld bioimpedance device in the clinic corridor. Having read your piece on what that device measures, I am no longer sure what I have been reassured about.

You describe the low-T3 pattern during energy restriction as benign adaptation. There is a body of opinion holding that it represents a genuine hypometabolic state requiring treatment. I do not hold that view but your readers will encounter it.

My HbA1c was 6.1 before starting and 6.0 after four months. My clinic recorded this as no improvement in glycaemic control. My continuous monitor says my average glucose fell by a fifth over the same period. Which is measuring what?

The claim that stopping does not leave you worse off than baseline is a group-level claim about trial arms. Individuals can and do overshoot. Your phrasing invites readers to conclude otherwise.

I take this for kidney disease, not for weight. Every piece of writing I encounter about stopping is about the weight coming back. It has taken me a year to find anybody willing to say plainly that the renal benefit accrued over years of treatment and nobody has tested what happens if I stop.

As a prescriber I would push back on your framing of the maintenance gap. We are not practising without evidence; we are practising on pharmacological inference, which is what clinicians do in every field where the trial has not been run. Calling it unevidenced makes reasonable practice sound reckless.

I have worked in aseptic fill for nineteen years and your section on media fills understates one thing. The scale is not the hard part. Running the simulation with every intervention the real process contains — every stopper jam, every environmental sample, every gowning break — is the hard part, and a simulation that omits the interventions is theatre with a growth medium in it.

Your table of responses records four declines citing research-use-only status, and you call that a legally sound answer. It is also the answer that ends the conversation. What would you have a supplier say instead?

You write that recombinant factor C is insensitive to the glucan branch of the cascade. It would be worth adding why anybody cares: cellulose filter media and certain paper wrappings shed glucans, and a laboratory that has chased a false positive through three repeat assays will never willingly go back to a reagent that responds to them.

Your endotoxin table gives vial 12 at 112 EU per vial and then declines to say whether that is dangerous. I understand why. It is still frustrating to read a figure of that size next to the sentence "arithmetic, not a safety assessment".

A small defence of the linear MALDI instrument. It is fast, it tolerates dirty samples, and for a synthesis chemist checking that a chain has grown by the residue intended it is entirely fit for purpose. The problem is not the instrument. It is printing its output on a release document.

I want to push back on the ginger paragraph. You describe the evidence as transferred from pregnancy and chemotherapy, which is accurate, and then include it in the table anyway. Either it belongs or it does not.

Your figures show diarrhoea at thirty-two per cent and constipation at twenty-three per cent in the same trial arm. I assumed one of these was an error until your mechanism section. It would be worth putting that explanation before the table rather than after it.

The gallbladder section says some of the excess is attributable to weight loss rather than the drug. If the drug causes the weight loss, is that not a distinction without a difference for the person who ends up in theatre?

Your figures show diarrhoea at thirty-two per cent and constipation at twenty-three per cent in the same trial arm. I assumed one of these was an error until your mechanism section. It would be worth putting that explanation before the table rather than after it.

I want to push back on the ginger paragraph. You describe the evidence as transferred from pregnancy and chemotherapy, which is accurate, and then include it in the table anyway. Either it belongs or it does not.

As an anaesthetist I read the perioperative section with interest and one objection. You frame disclosure as the patient obligation. In my experience the failure is more often ours: the pre-assessment questionnaire in my own institution did not include these drugs until eighteen months after the first guidance appeared.

The gallbladder section says some of the excess is attributable to weight loss rather than the drug. If the drug causes the weight loss, is that not a distinction without a difference for the person who ends up in theatre?

You note that symptom burden does not predict weight outcome. This is the single most useful sentence I have read about this treatment. I spent four months believing that feeling well meant it was not working and considered increasing my dose on that basis alone.

Eleven days in customs, and you describe it as a structural feature rather than a scandal. Why the restraint? A shipper advertising a cold chain that demonstrably does not survive a routine examination is making a claim it cannot support.

Your section on freezing reconstituted solution stops short of the obvious question, which I will therefore ask. If a phosphate buffer shifts pH substantially on freezing, does that not mean the freezer is actively worse than the refrigerator for a buffered formulation, rather than merely unproven?

I have shipped temperature-sensitive material commercially for eleven years and your coolant arithmetic is right but generous. You assume the pack starts fully frozen. In practice packs are pulled from a freezer that is opened forty times a day, and a pack that starts at minus four with a soft core has lost a fair share of its budget before the box is closed.

Nothing in this file addresses what to do when you realise mid-week that you have made an error. I gave double my dose on a Sunday and could find no guidance anywhere about what that meant.

I gave myself a tenth of my intended dose for five weeks. I had been using insulin syringes, ran out, and used the 1 mL syringes that came with the vials, which are marked in millilitres. I did not notice because the plunger was in roughly the same place. Nobody warned me these were different scales.

A quibble on your dead-space figure. You give two to seven microlitres for insulin-type needles, which is right for fixed-needle syringes, but the detachable pen needle plus syringe hub combinations sold in this market are considerably worse and you should say so.

I submitted a vial to one of these services last year, got a result three points below what the vendor advertised, and did not know what to do with it. Your article explains why: I had one measurement on one vial, no method comparison, and no way to know if my vial was representative. I still do not know what to do with it, but I understand the shape of not knowing.

I run analytical services and I object to the framing of your blind comparison. You bought our cheapest tier, published the number it produced alongside a competitor’s most thorough package, and called the result a spread. It is not a spread. It is three different products, priced accordingly, and your own table says so two columns to the right of the headline figure.

Your suggestion that laboratories publish the fact of a submission while keeping the result confidential is the first proposal I have read in this area that a laboratory could actually implement without breaching a client obligation. I have raised it internally.

Your figures show diarrhoea at thirty-two per cent and constipation at twenty-three per cent in the same trial arm. I assumed one of these was an error until your mechanism section. It would be worth putting that explanation before the table rather than after it.

I want to push back on the ginger paragraph. You describe the evidence as transferred from pregnancy and chemotherapy, which is accurate, and then include it in the table anyway. Either it belongs or it does not.

Your selection-effect model assumes a supplier publishes results above a fixed threshold. Real behaviour is surely more complicated: a supplier might publish a poor result on a batch it has withdrawn, or publish everything for a period to establish credibility and then stop. The arithmetic is fine and the behavioural assumption is a cartoon.

As a buyer I found the section on who chose the vial genuinely clarifying and slightly deflating. I have been treating vendor-published reports as equivalent to my own submissions for two years, and on your account they are not equivalent by an amount that cannot be measured.

Your table of degradation pathways lists racemisation and then says it is essentially never reported. If it is never reported, on what basis do you list it as a real risk rather than a theoretical one?

The mean kinetic temperature explanation is the clearest I have read anywhere, including in the training my employer paid for. I have printed the sidebar and put it on the wall of the dispatch room.

On amber glass: it is not merely cheap, it is standard in the wider chemical supply trade for anything with a chromophore. The fact that this market ships peptides in clear glass is a sign of who is doing the filling more than of any decision about photostability.

Parcel 7 reached thirty-eight degrees for nearly four hours and you then tell readers not to worry unduly. I accept the solid-state argument. I would still like to know what the material looked like on analysis, and your article does not say.

Your section on freezing reconstituted solution stops short of the obvious question, which I will therefore ask. If a phosphate buffer shifts pH substantially on freezing, does that not mean the freezer is actively worse than the refrigerator for a buffered formulation, rather than merely unproven?

You put every documentary finding to the company before publication, which is admirable and also means you are letting companies that do not reply escape coverage entirely. Silence should have a cost.